We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Sanskar College of Pharmacy and Research
The chronic, progressive autoimmune disease known as rheumatoid arthritis (RA) is typified by systemic problems, cartilage degradation, and ongoing synovial inflammation. Conventional pharmacological approaches, such as biologics, disease-modifying antirheumatic drugs (DMARDs), and nonsteroidal anti-inflammatory drugs (NSAIDs), are frequently linked to poor bioavailability, systemic toxicity, off-target effects, and variable patient response, despite notable therapeutic advancements. Because of these constraints, effective and targeted medication delivery methods must be developed. Systems based on lipid nanoparticles have shown promise as nanocarriers that can maximize therapeutic effectiveness while reducing side effects. The categorization, structural properties, and formulation techniques of lipid nanoparticles such as liposomes, lipid–polymer hybrid nanoparticles, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) are covered in detail in this study. A critical analysis is conducted of their function in enhancing drug solubility, stability, controlled release, and targeted delivery to inflammatory synovial regions. The mechanisms of active ligand-mediated targeting, macrophage-specific delivery, stimuli-responsive systems, and passive targeting through the increased permeability and retention (EPR) effect are discussed. Additionally, a summary of current developments in the administration of biologics, gene therapies, NSAIDs, and DMARDs like methotrexate and leflunomide is provided, with a focus on preclinical and new clinical data. Current issues including large-scale production, long-term stability, safety concerns, and regulatory considerations are also included in the study. Lastly, future directions are examined with an emphasis on multifunctional smart lipid platforms, artificial intelligence-guided formulation design, and customized nanomedicine. Drug delivery methods based on lipid nanoparticles give better therapeutic results and open the door for next-generation precision nanomedicine techniques, making them a revolutionary approach to the treatment of RA.
A chronic, systemic inflammatory disease that mostly affects synovial joints, rheumatoid arthritis (RA) causes progressive bone erosion, cartilage degradation, and functional impairment. It is more common in women and affects between 0.5 and 1% of people worldwide. Prolonged synovial inflammation, pannus development, immune cell infiltration (T cells, B cells, and macrophages), and an excess of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 are the hallmarks of the condition. Immune dysregulation, environmental factors, and genetic vulnerability interact intricately throughout the development of RA. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are examples of autoantibodies that contribute to the development of immune complexes and persistent inflammation. Joint injury is further exacerbated by nuclear transcription factor activation, mitochondrial dysfunction, and chronic oxidative stress. Untreated RA causes irreparable joint abnormalities, respiratory and cardiovascular problems, and a worse quality of life [1]. About 40–50 million people worldwide suffer from rheumatoid arthritis (RA), an inflammatory disease that affects 0.5–1% of adults. Geographically, the incidence varies; greater rates (0.8–1.2%) have been observed in North America and Northern Europe than in Asia and Africa (0.2–0.7%). According to epidemiological research, the prevalence in India is between 0.5 and 0.75%. About 20 to 50 new cases of RA are reported for every 100,000 people each year; the incidence varies according on factors such as diagnostic criteria, ethnicity, and environmental exposure [2]. With a female-to-male ratio of 2-3:1, RA exhibits a significant gender gap, which may be due to a hormonal or hereditary component to disease risk. Although the illness can appear at any age, the peak age of onset usually happens between 30 and 60. With heritability estimates of 50–60%, genetic predisposition is a major factor, especially when it comes to HLA-DRB1 shared epitope alleles. RA is linked to a 1.5–2-fold greater risk of death compared to the general population, in addition to joint-related disability and increased systemic consequences, including cardiovascular disease. Life expectancy may be shortened by three to ten years in severe or poorly managed instances. RA's substantial impact on public health is further highlighted by the substantial socioeconomic burden it places owing to the need for ongoing treatment, job incapacity, and decreased productivity [3].
Nonsteroidal anti-inflammatory medicines (NSAIDs), corticosteroids, disease-modifying antirheumatic medications (DMARDs) including leflunomide and methotrexate, and biologic therapies that target certain cytokines are all part of the current pharmacological care of RA. These treatments have a number of drawbacks even if they dramatically lower inflammation and halt the course of the illness [4]. Poor bioavailability, quick systemic clearance, non-specific distribution, and dose-dependent toxicity are common characteristics of oral and parenteral medications. Adverse cardiovascular, renal, and gastrointestinal consequences are linked to long-term usage of corticosteroids and NSAIDs. While biologics are costly and may make a person more susceptible to infections, conventional DMARDs have the potential to induce hepatotoxicity, bone marrow suppression, and immunosuppression. Furthermore, the effectiveness of treatment is limited by inconsistent patient response, frequent dosage, and inadequate drug accumulation in inflamed joints. These difficulties show how novel medication delivery strategies that maximize site-specific targeting and reduce systemic exposure are required. A considerable percentage of rheumatoid arthritis patients do not experience full remission, even with the availability of sophisticated treatment drugs. Long-term treatment is made more difficult by drug resistance, biologic immunogenicity, and the requirement for combination therapy [5]. Biologics administered parenterally frequently need hospital stays or skilled staff, which lowers patient compliance and raises healthcare expenses. Additionally, with continued medication, systemic immunosuppression puts patients at risk for cancer and opportunistic infections. Higher systemic dosages are required to achieve therapeutic success due to standard formulations' inability to selectively concentrate medicines inside inflammatory synovial regions, which exacerbates side effects [6]. These drawbacks highlight the pressing need for sophisticated drug delivery methods that can enhance intra-articular drug accumulation, improve pharmacokinetic profiles, decrease the frequency of dose, and ultimately improve patient adherence and overall therapeutic results.
Systems based on targeted nanocarriers have shown promise in addressing the shortcomings of traditional RA treatment. Improved drug solubility, increased stability, controlled release, and biocompatibility are some benefits of lipid-based nanoparticles, which include liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) [7]. Through the enhanced permeability and retention (EPR) effect, passive targeting is made possible by the increased vascular permeability found in inflammatory synovial tissues. Additionally, absorption by activated macrophages and synoviocytes can be enhanced by active targeting techniques that include ligand conjugation (e.g., folate, antibodies, peptides). Moreover, lipid nanoparticles can promote intracellular delivery and shield labile medications such as biologics and nucleic acids from deterioration. Targeted nanocarriers have a great deal of promise to boost therapeutic effectiveness while lowering side effects by enhancing pharmacokinetic and pharmacodynamic characteristics [8]. Additionally, lipid-based nanocarriers offer possibilities for stimulus-responsive and multifunctional delivery methods in the treatment of rheumatoid arthritis. Acidic pH, increased reactive oxygen species (ROS), and overexpression of certain enzymes are characteristics of the inflammatory milieu of RA joints that can be used to create smart nanoparticles with site-specific medication release. Targeting ligands or polyethylene glycol (PEG) surface modification improves circulation time and selective accumulation in inflammatory synovium. Furthermore, lipid nanoparticles allow the co-delivery of several therapeutic agents, including immunomodulators and anti-inflammatory medications, resulting in dosage reduction and synergistic benefits. They are ideal for long-term treatments for chronic diseases like RA because of their biodegradable and biocompatible lipid matrix, which also reduces systemic toxicity. Lipid nanocarriers are positioned as next-generation platforms for accurate, effective, and patient-friendly RA therapy techniques due to these benefits taken together [9].
The objective of this study is to present a thorough and critical assessment of drug delivery systems based on lipid nanoparticles in the treatment of RA. Disease pathophysiology, lipid nanoparticle categorization and structural characteristics, formulation and characterization techniques, and passive and active targeting mechanisms are all covered. It also includes new preclinical and clinical developments including gene-based therapies, biologics, NSAIDs, and DMARDs that are administered via lipid nanocarriers [10]. Along with examining potential future developments like customized nanomedicine, AI-assisted formulation design, and multifunctional smart lipid platforms, the paper also discusses present issues with stability, scalability, regulatory approval, and long-term safety. The overall goal of this study is to close the gap between translational clinical applications in RA treatment and experimental nanotechnology research [11]
METHODOLOGY
To find pertinent research on lipid nanoparticle-based drug delivery systems in rheumatoid arthritis, a thorough and methodical literature search was carried out. From January 2000 to August 2025, electronic databases such as PubMed, Scopus, and Web of Science were searched. Only peer-reviewed English-language publications were included in the search. To guarantee thorough coverage, additional references were found by manually reviewing the bibliographies of chosen papers [12].
The search strategy incorporated combinations of Medical Subject Headings (MeSH) and free-text terms using Boolean operators (AND, OR). Primary keywords included: “Rheumatoid arthritis,” “lipid nanoparticles,” “solid lipid nanoparticles (SLNs),” “nanostructured lipid carriers (NLCs),” “liposomes,” “lipid–polymer hybrid nanoparticles,” “targeted drug delivery,” “nanomedicine,” “DMARDs,” and “methotrexate delivery.” Synonyms and related terms were adapted according to database indexing systems to maximize retrieval sensitivity and specificity.
Studies were included if they: (i) investigated lipid-based nanoparticle systems for RA therapy; (ii) reported formulation development, characterization, in vitro, in vivo, or clinical evaluation; and (iii) were original research articles, systematic reviews, or meta-analyses. Preclinical animal studies evaluating therapeutic efficacy and targeting strategies were also considered. Studies were excluded if they: (i) focused on non-lipid nanocarriers (e.g., metallic or polymeric nanoparticles without lipid components); (ii) were conference abstracts, editorials, or non-peer-reviewed reports; (iii) lacked sufficient methodological details; or (iv) were not available in English.
The study selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Initially, all identified records were exported into reference management software, and duplicates were removed. Titles and abstracts were screened independently for relevance, followed by full-text assessment of potentially eligible articles. Studies meeting predefined inclusion criteria were finally selected for qualitative synthesis. A PRISMA flow diagram was constructed to illustrate the identification, screening, eligibility, and inclusion stages.
Relevant data were systematically extracted using a standardized data extraction form. Extracted parameters included type of lipid nanoparticle, drug incorporated, preparation method, particle size, zeta potential, entrapment efficiency, release profile, targeting strategy, in vitro and in vivo outcomes, and safety evaluation. The findings were synthesized qualitatively, highlighting formulation trends, therapeutic outcomes, advantages, limitations, and translational potential. Comparative analysis was performed to identify key advancements and research gaps in lipid nanoparticle-based RA therapy.
A complicated interaction between genetic predisposition, environmental exposures, and dysregulated immune responses causes rheumatoid arthritis. The HLA-DRB1 alleles that encode the "shared epitope," which heightens vulnerability to aberrant antigen presentation, are associated with the highest genetic connection. Cigarette smoking, periodontal diseases (such Porphyromonas gingivalis), and occupational toxins are examples of environmental variables that encourage post-translational protein changes, including citrullination. Loss of self-tolerance results from the immune system identifying these altered proteins as neoantigens [13]. One characteristic of RA is the development of autoantibodies. Anti-citrullinated protein antibodies (ACPAs) bind citrullinated peptides specifically, whereas rheumatoid factor (RF) targets the Fc region of IgG. By forming immunological complexes and depositing in synovial tissues, these autoantibodies increase inflammation and activate complement pathways. CD4 T helper cells (Th1 and Th17 subsets) receive antigens from activated dendritic cells, which cause them to release pro-inflammatory cytokines and promote the development of B cells. B cells also help by presenting antigens and producing autoantibodies. A prolonged inflammatory milieu is created when macrophages penetrate the synovium and produce inflammatory mediators. The immunological underpinning of RA is comprised of ongoing immune cell activation and a loss of immune tolerance [14].
A highly integrated cytokine network maintains the inflammatory environment in RA. Tumor necrosis factor-alpha (TNF-α) is a key mediator among them, coordinating the production of adhesion molecules, growth factors, chemokines, and other cytokines. TNF-α promotes leukocyte migration into synovial tissue by increasing endothelial activity. Additionally, it triggers the production of more inflammatory mediators by macrophages and synovial fibroblasts, establishing a positive feedback loop. Through the induction of matrix metalloproteinases (MMPs) and the suppression of the formation of cartilage extracellular matrix components such collagen type II and proteoglycans, interleukin-1 beta (IL-1β) plays a crucial role in the deterioration of cartilage. Local joint inflammation and systemic symptoms such as osteoporosis, tiredness, and chronic disease anemia are both influenced by interleukin-6 (IL-6) [15]. These cytokines trigger the transcription of inflammatory genes by activating intracellular pathways such NF-κB, MAPK, and JAK-STAT signaling. This cytokine cascade's persistence causes gradual structural joint deterioration and persistent synovitis [16].
Synovial hyperplasia is one of the defining pathological characteristics of RA. The synovial membrane normally has a thin lining layer, but in RA, the proliferation of fibroblast-like synoviocytes (FLS) and immune cell infiltration cause this layer to greatly enlarge. A pannus, an invasive granulation tissue, is created by the hyperplastic synovium and extends across the surfaces of cartilage [17]. In RA, fibroblast-like synoviocytes develop aggressive, tumor-like traits, including as increased migratory ability, resistance to apoptosis, and an overabundance of degradative enzymes and inflammatory cytokines. These cells release aggrecanases and matrix metalloproteinases (MMP-1, MMP-3, and MMP-9) that break down cartilage's collagen and proteoglycans. Bone erosion results from the simultaneous promotion of osteoclast precursor differentiation into mature osteoclasts by the production of receptor activator of nuclear factor kappa-B ligand (RANKL). The recruitment of inflammatory cells and the growth of pannus are further supported by angiogenesis in the synovium. When combined, these processes cause permanent deformity and joint damage [18].
One important factor in the development and course of RA is oxidative stress. In inflammatory joints, activated neutrophils, macrophages, and synovial cells produce an excess of reactive oxygen species (ROS) and reactive nitrogen species (RNS). Lipid peroxidation, protein oxidation, and DNA damage are all influenced by elevated amounts of superoxide anion, hydrogen peroxide, and nitric oxide [19]. Tissue damage is made worse by an imbalance between the production of pro-oxidants and antioxidant defense mechanisms such reduced glutathione, superoxide dismutase (SOD), and catalase. In addition to directly harming bone and cartilage, oxidative stress also triggers redox-sensitive transcription factors like AP-1 and NF-κB, which increases inflammatory signaling and cytokine production. Furthermore, ROS accelerate cartilage degradation by promoting chondrocyte death and preventing the formation of extracellular matrix. Oxidative stress is therefore a key therapeutic target in the therapy of RA because it works in concert with immunological and cytokine-mediated pathways to maintain structural joint damage and chronic inflammation [20].
Made of physiological and biodegradable lipids, lipid nanoparticles are a flexible family of nanocarriers intended to enhance medication solubility, stability, bioavailability, and targeted administration. Lipid nanoparticles can be generically categorized as liposomes, lipid–polymer hybrid nanoparticles, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) based on their structural organization and content. Because of their special structure, they can encapsulate hydrophilic, lipophilic, and amphiphilic medications, which makes them ideal for long-term inflammatory conditions like rheumatoid arthritis [21].
First-generation lipid nanocarriers made of lipids that stay solid at body temperature and room temperature are called solid lipid nanoparticles (SLNs). Glyceryl monostearate, stearic acid, and cetyl palmitate are examples of common solid lipids that are stabilized by surfactants like lecithin or polysorbates. In terms of structure, SLNs are made up of a solid lipid core matrix that contains amorphous clusters of molecularly distributed medication. Better defense against chemical deterioration and regulated medication release are offered by the solid matrix. SLNs offer better pharmacokinetics and increased cellular absorption, with particle sizes usually falling between 50 and 300 nm. But drawbacks including a low drug loading capacity and the possibility of drug ejection during storage because of lipid crystallization have spurred the creation of sophisticated systems like NLCs [22].
Second-generation lipid nanoparticles called nanostructured lipid carriers (NLCs) were created to address the shortcomings of SLNs. They have an imperfect or less organized lipid matrix because they are made up of a mixture of liquid and solid lipids. By introducing vacuum areas into the matrix, this structural alteration increases the drug loading capacity and lowers the chance of drug ejection. Compared to SLNs, NLCs show superior control of drug release patterns, increased stability, and higher entrapment efficiency. NLCs can form a variety of structural models, including numerous oil-in-fat-in-water systems, amorphous types, and imperfect crystal types, depending on the lipid content. They are especially useful for encapsulating lipophilic anti-inflammatory medications used in RA treatment because of their flexible interior structure [23].
Liposomes are spherical vesicular structures with an aqueous core surrounded by one or more phospholipid bilayers. They are more biocompatible and can merge with cellular membranes because of their structural resemblance to actual cell membranes. Drugs that are hydrophilic in the aqueous core and lipophilic in the lipid bilayer can both be encapsulated by liposomes. Based on their size and lamellarity, they are categorized as small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), and multilamellar vesicles (MLVs). PEGylation is one surface modification technique that decreases opsonization and increases circulation time. Because of its adaptability and safety record, liposomes are being investigated extensively for the targeted administration of biologics, gene therapies, and anti-inflammatory medications [24].
The benefits of lipid-based systems and polymeric nanoparticles are combined in lipid–polymer hybrid nanoparticles. In terms of structure, they usually have a lipid coating that improves stability and biocompatibility around a polymeric core (such PLGA) that encapsulates the medication. This core-shell design shields the medication from deterioration while allowing for regulated and prolonged drug release [25]. Targeting ligands can be used to functionalize the lipid shell, improving its selective accumulation in inflammatory synovial tissues. These hybrid devices are potential options for combined drug administration and advanced RA treatment because of their enhanced mechanical stability, increased drug payload, and adjustable release kinetics [26].
Fig 1: Different Types of Lipid Nano-particles [26]
Compared to traditional dosage forms including pills, capsules, and injectable solutions, lipid nanoparticles provide a number of benefits. They offer regulated or prolonged drug release, increase bioavailability, and make poorly water-soluble medications more soluble. Their nanoscale size facilitates passive targeting to inflammatory regions via improved permeability and retention (EPR) [27]. Lipid nanoparticles also lessen systemic toxicity by facilitating site-specific delivery and reducing off-target dispersion. They shield labile substances from enzymatic breakdown, such as proteins, peptides, and nucleic acids. Lipid nanoparticles differ from conventional formulations in many ways, such as better patient compliance, less frequent dosage, and the possibility of multifunctional or stimuli-responsive changes. When taken as a whole, these structural and functional benefits make lipid nanoparticles revolutionary platforms for contemporary drug delivery, especially for chronic inflammatory diseases like RA [28].
Table 1: Classification and Structural Features of Lipid Nanoparticles in Rheumatoid Arthritis Therapy
|
Type of Lipid Nanoparticle |
Composition |
Structural Characteristics |
Drug Loading Capacity |
Key Advantages |
Limitations |
Relevance in RA Therapy |
|
Solid Lipid Nanoparticles (SLNs) |
Solid lipids (glyceryl monostearate, stearic acid, cetyl palmitate) + surfactants (polysorbates, lecithin) |
Solid lipid core matrix with drug molecularly dispersed or in amorphous clusters; particle size 50–300 nm |
Moderate |
Controlled release, improved stability, protection from degradation, biocompatibility |
Limited drug loading, risk of drug expulsion due to lipid crystallization |
Suitable for sustained delivery of anti-inflammatory drugs; enhances bioavailability [29] |
|
Nanostructured Lipid Carriers (NLCs) |
Blend of solid and liquid lipids + surfactants |
Imperfect or less-ordered lipid matrix with void spaces; improved internal structure |
High |
Higher entrapment efficiency, reduced drug expulsion, better stability, modulated release |
Slightly complex formulation process |
Ideal for lipophilic anti-RA drugs; improved therapeutic efficacy and reduced toxicity |
|
Liposomes |
Phospholipid bilayers ± cholesterol |
Spherical vesicles with aqueous core; may be SUV, LUV, or MLV |
Suitable for both hydrophilic & lipophilic drugs |
Excellent biocompatibility, membrane mimicry, PEGylation possible, targeted modification |
Stability issues, possible leakage, higher production cost |
Effective for targeted delivery of DMARDs, biologics, and gene therapeutics [30] |
|
Lipid–Polymer Hybrid Nanoparticles |
Polymeric core (e.g., PLGA) + lipid shell |
Core–shell structure; polymer core encapsulates drug, lipid shell enhances stability |
High |
Controlled & sustained release, mechanical stability, tunable kinetics, ligand functionalization |
More complex manufacturing |
Promising for combination therapy and targeted synovial delivery |
|
Overall Advantages Over Conventional Systems |
Physiological, biodegradable lipids |
Nanoscale systems enabling EPR-mediated accumulation |
Enhanced compared to conventional dosage forms |
Improved solubility, bioavailability, reduced systemic toxicity, controlled release, protection of labile drugs |
Scale-up and regulatory challenges |
Enhances site-specific delivery to inflamed joints, improves patient compliance [31] |
In rheumatoid arthritis, targeted medication delivery aims to reduce systemic exposure and side effects while increasing drug concentration in inflammatory synovial joints. Numerous biological targets for nanoparticle-mediated delivery are provided by the pathological milieu of RA, which is marked by neovascularization, increased vascular permeability, immune cell infiltration, oxidative stress, and acidic pH. By using passive, active, cellular, and stimuli-responsive targeting methods, lipid nanoparticles may be designed to take advantage of these characteristics [31].
The Enhanced Permeability and Retention (EPR) effect, which is also seen in tumors and tissues with chronic inflammation, is the main basis for passive targeting in RA. Persistent inflammation in RA promotes synovial membrane angiogenesis. These newly created blood arteries, however, have reduced vascular integrity and increased endothelial fenestrations, making them structurally aberrant. These leaky vasculatures allow nanoparticles that are between 50 and 300 nm in size to extravasate into the synovial interstitium. Moreover, longer retention of nanoparticles due to poor lymphatic outflow in inflammatory joints lengthens the duration of treatment and increases local drug concentration. Because of their nanoscale size and biocompatibility, lipid-based systems including liposomes, NLCs, and SLNs are especially well-suited for passive targeting. By increasing drug accumulation without requiring intricate surface modification, passive targeting improves pharmacokinetics and lowers systemic toxicity. Targeting effectiveness, however, may be impacted by patient and disease stage variations in vascular permeability, underscoring the necessity of complementing approaches [32].
The process of functionalizing the surfaces of nanoparticles with ligands that bind selectively to overexpressed receptors on inflammatory synovial cells is known as active targeting. Increased expression of receptors such folate receptors, CD44, ICAM-1, scavenger receptors, and integrins is seen in RA-associated activated macrophages, dendritic cells, endothelial cells, and fibroblast-like synoviocytes. The surfaces of lipid nanoparticles can be conjugated with ligands including folic acid, hyaluronic acid, monoclonal antibodies, peptides, transferrin, and aptamers. Nanoparticles experience receptor-mediated endocytosis upon ligand–receptor contact, which improves intracellular drug delivery. By reducing off-target effects, this method greatly increases treatment effectiveness and selectivity. PEGylation is frequently used in conjunction with ligand conjugation to prolong systemic circulation and inhibit the reticuloendothelial system's (RES) quick clearance. For the delivery of strong DMARDs, biologics, and gene treatments that need exact intracellular localization, active targeting is very beneficial [33].
Pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 are produced by macrophages, which are important effector cells in the pathophysiology of RA. These cytokines prolong joint degradation and synovial inflammation. Nanoparticles can be engineered to take advantage of the increased phagocytic activity of activated macrophages for selective absorption. By attaching to appropriate surface receptors, surface modification with mannose, folate, or certain antibodies enhances macrophage-specific targeting. Additionally, fibroblast-like synoviocytes (FLS) are essential for the development of pannus and the breakdown of cartilage. Adhesion molecules and CD44 receptors are overexpressed in these cells. Lipid nanoparticles coated with hyaluronic acid have the ability to attach to CD44 specifically, facilitating synoviocyte internalization. Cell-specific targeting directly inhibits inflammatory signaling pathways inside important pathogenic cells, improves therapeutic concentration at the site of inflammation, and lessens systemic immunosuppression. Lower adverse effect profiles and better treatment results are two benefits of this approach [34].
Drugs are released by stimuli-responsive, or "smart," nanocarriers in response to pathological circumstances specific to the RA microenvironment. Acidic pH (≈6.5–6.8), increased reactive oxygen species (ROS), increased enzyme activity (e.g., matrix metalloproteinases), and greater quantities of inflammatory mediators are all characteristics of inflammatory joints. Acid-labile linkers or pH-responsive lipids that disintegrate in acidic environments are used to create pH-sensitive lipid nanoparticles, which allow for targeted medication release inside inflammatory synovial fluid. To ensure selective drug release, ROS-responsive systems use oxidation-sensitive linkages that break down in high oxidative stress conditions. Site-specific release in regions of active cartilage degradation is made possible by enzyme-sensitive carriers, which are made to break down in the presence of matrix metalloproteinases. Precision delivery is also being investigated using thermoresponsive and externally triggered technologies (such as magnetic field-responsive carriers or ultrasound). By limiting drug activity to diseased locations, these intelligent nanocarriers reduce early drug leakage, increase treatment precision, and increase safety [35].
Optimal formulation design and comprehensive physicochemical characterization are essential for the successful development of lipid nanoparticle-based medication delivery systems for rheumatoid arthritis. Particle size, drug loading, release kinetics, stability, and targeted effectiveness are all directly impacted by formulation techniques. Reproducibility, therapeutic effectiveness, and translational feasibility are all guaranteed by accurate characterisation.
Lipid–polymer hybrid nanoparticles, liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) are all made using different preparation techniques. The physicochemical characteristics of the medicine, the required stability, scalability, and desirable particle size all influence the procedure selection. Typical methods of preparation include of:
Each method influences particle morphology, entrapment efficiency, scalability, and reproducibility, making process optimization essential.
Table 2: Preparation Techniques for Lipid Nanoparticle Systems
|
Preparation Technique |
Principle |
Suitable Nanocarrier Type |
Key Advantages |
Limitations |
|
High-Pressure Homogenization (HPH) |
Lipid–drug mixture is forced through narrow gaps at high pressure to reduce particle size; can be performed under hot or cold conditions |
SLNs, NLCs |
Scalable, reproducible, suitable for large-scale production |
High energy input, possible thermal degradation (hot method) [38] |
|
Emulsification–Solvent Evaporation |
Formation of oil-in-water emulsion followed by evaporation of organic solvent to form nanoparticles |
SLNs, NLCs, Hybrid nanoparticles |
Suitable for lipophilic drugs, controlled particle formation |
Use of organic solvents, potential residual solvent toxicity |
|
Microemulsion Technique |
Warm microemulsion is formed and rapidly dispersed into cold aqueous phase to solidify nanoparticles |
SLNs, NLCs |
Simple process, uniform particle size |
Requires high surfactant concentration [39] |
|
Ultrasonication / High-Speed Stirring |
Mechanical energy applied to reduce droplet size and form nanoparticles |
SLNs, NLCs |
Simple, cost-effective, suitable for lab-scale |
Limited scalability, potential metal contamination from probe |
|
Thin-Film Hydration Method |
Formation of dry lipid film followed by hydration and size reduction (e.g., sonication/extrusion) |
Liposomes |
Well-established, suitable for hydrophilic and lipophilic drugs |
Batch variability, scale-up challenges [40] |
|
Solvent Injection / Nanoprecipitation |
Rapid mixing of lipid/polymer solution with aqueous phase leading to nanoparticle formation |
Lipid–Polymer Hybrid Nanoparticles |
Simple, controlled particle size, mild conditions |
Requires solvent removal, scale-up considerations [41] |
Several formulation variables significantly impact the performance of lipid nanoparticles:
Optimizing these parameters ensures reproducible nanoparticle formation with desired therapeutic characteristics.
Particle size is a critical determinant of biodistribution, cellular uptake, and passive targeting efficiency. For RA therapy, nanoparticles typically range from 50–300 nm to exploit the enhanced permeability and retention (EPR) effect. Smaller particles may exhibit improved penetration into inflamed synovium, while excessively small particles may undergo rapid clearance.
The Polydispersity Index (PDI) indicates size distribution uniformity. A PDI value below 0.3 suggests homogeneous particle distribution and good formulation stability [43].
Zeta potential reflects surface charge and predicts colloidal stability. Values greater than ±30 mV generally indicate good electrostatic stabilization. Surface charge also influences cellular uptake and interaction with biological membranes. These parameters are typically measured using dynamic light scattering (DLS) and electrophoretic mobility techniques [44].
Two crucial measures of formulation effectiveness are drug loading capacity (DL%) and entrapment efficiency (EE%). High entrapment efficiency reduces medication waste while guaranteeing a sufficient therapeutic payload. Lipid matrix composition, drug solubility in the lipid phase, preparation technique, and lipid crystallinity all affect entrapment efficiency. Because of their poor lipid matrix, NLCs often show more drug loading than SLNs. For chronic illnesses like RA, where sustained therapeutic levels are necessary, drug loading optimization is especially crucial [45].
To assess release kinetics and forecast in vivo performance, in vitro drug release studies are conducted. Commonly employed techniques include membrane diffusion methods, dialysis bag diffusion, and Franz diffusion cells. Depending on the formulation design, release profiles can have zero-order, first-order, Higuchi, or Korsmeyer-Peppas kinetics. To lessen systemic toxicity and dosage frequency, controlled and prolonged release is preferred [46]. Studies of stability evaluate a product's chemical and physical stability at different storage temperatures (e.g., 4°C, 25°C, 40°C). Particle size, PDI, zeta potential, drug content, and visual appearance are among the parameters that are tracked over time. For long-term storage, lipid crystallization, aggregation, and drug leakage must be avoided. Lipid nanoparticle systems are guaranteed to provide consistent quality, therapeutic effectiveness, and translational potential in the management of RA by thorough formulation optimization and characterization [47].
Lipid-based nanocarriers, including liposomes, lipid–polymer hybrid nanoparticles, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), have drawn a lot of interest in the treatment of rheumatoid arthritis (RA). Through passive targeting mechanisms, RA's chronic synovial inflammation, increased vascular permeability, and macrophage infiltration foster the formation of nanoparticles. Furthermore, active targeting of inflammatory synovial tissue is made possible by surface modification. Enhancing medication retention in joints, lowering systemic toxicity, increasing bioavailability, and offering prolonged or stimuli-responsive drug release are the goals of these systems [48].
Diclofenac, Ibuprofen, and Indomethacin are examples of nonsteroidal anti-inflammatory medications (NSAIDs) that are frequently used for RA symptoms. Long-term oral treatment, however, carries hazards for cardiovascular disease, renal problems, and gastrointestinal discomfort. By making NSAIDs more soluble and allowing for regulated release, lipid nanoparticles can lessen the negative effects associated with peaks. In experimental models of arthritis, topical and transdermal lipid nanocarriers have demonstrated improved skin penetration and sustained anti-inflammatory effects. These formulations aid in achieving efficient pain management with less toxicity by maximizing local drug concentration in inflammatory joints and reducing systemic exposure. Compared to traditional dose forms, preclinical studies show less edema and inhibition of inflammatory cytokines. Because of their well-established pharmacological safety profiles and straightforward regulatory routes, NSAID-loaded lipid systems are among the most promising options for clinical use from a translational standpoint [49].
Although disease-modifying antirheumatic medications (DMARDs) are crucial for slowing the course of RA, their toxicity and poor absorption restrict their long-term usage.
The first-line DMARD for treating RA is still methotrexate. By passive targeting and, in some situations, receptor-mediated absorption, lipid-based nanoformulations improve its delivery to inflammatory synovial tissue. In collagen-induced arthritis models, encapsulation enhances therapeutic effectiveness, permits prolonged drug release, and lowers systemic exposure. In comparison to free methotrexate, studies have shown superior histopathological results, less hepatotoxicity, and lower joint inflammation [50]. Leflunomide has also been added to liposomal and NLC systems to increase solubility and extend drug release. Preclinical results show improved safety profiles and increased anti-arthritic efficacy. Despite its promise, translation to clinical practice necessitates a thorough assessment of pharmacoeconomic factors, long-term toxicity, and the viability of large-scale manufacture [51].
Treatment for RA has changed as a result of biologic treatments that target inflammatory cytokines. TNF-α is efficiently neutralized by drugs like etanercept and adalimumab, which lessen joint degradation and inflammation. However, these biologics are costly, must be administered parenterally, and have the potential to trigger immunogenic reactions.
A flexible framework for improving the tissue targeting and stability of biologics is offered by lipid nanoparticles. Proteins can be shielded from deterioration by encapsulation, which may also increase circulation time. Furthermore, the delivery of small interfering RNA (siRNA) and other nucleic acid therapies targeted at inhibiting pro-inflammatory genes is being investigated using lipid-based systems. The translational viability of such approaches in inflammatory illnesses is supported by the clinical effectiveness of lipid nanoparticle platforms in mRNA delivery, as demonstrated by BNT162b2. Immune activation, stability, and regulatory complexity are still major obstacles, though [52].
Lipid nanoparticle formulations have been shown in several preclinical investigations in collagen-induced and adjuvant-induced arthritis models to improve pharmacokinetics, boost synovial drug accumulation, and considerably lower inflammatory markers. Nano-based methods continuously demonstrate better control over joint swelling and histopathological damage as compared to traditional formulations. The field of clinical translation is developing slowly. Early-phase clinical testing of several liposomal and nanoemulsion-based anti-inflammatory compositions has revealed enhanced tolerability and long-lasting therapeutic benefits. Nonetheless, the majority of gene-delivery and nano-DMARD systems are still in the preclinical stage [53]. Regulatory approval requires long-term safety data, consistent production processes, and a thorough toxicological evaluation. All things considered, drug delivery methods based on lipid nanoparticles offer a potential translational link between clinical RA therapy and experimental innovation. The future of precision and targeted rheumatology treatments lies in biologic and gene-based nanotherapies, even if NSAID and DMARD-loaded systems are closer to real-world use [54].
LIMITATIONS AND CHALLENGES
Lipid-based nanocarriers for rheumatoid arthritis (RA) have shown encouraging therapeutic results, but their large-scale clinical translation is hampered by a number of scientific, technological, and regulatory obstacles. Although liposomes, lipid–polymer hybrid systems, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs) exhibit enhanced bioavailability and targeted delivery, their successful commercialization necessitates overcoming obstacles pertaining to stability, scalability, regulatory approval, and long-term safety [55].
The physical and chemical instability of lipid nanoparticles during storage is one of their main drawbacks. Drug ejection may eventually result via lipid crystallization, polymorphic transitions, and particle aggregation, especially in SLNs. Reproducibility and therapeutic efficacy may be impacted by changes in zeta potential and particle size distribution that occur during storage. Stability is further jeopardized by lipid hydrolysis and oxidation, particularly in formulations that contain unsaturated fatty acids. Phospholipid oxidation and drug leakage from encapsulation are still major issues for liposomal systems. It is frequently important to maintain ideal storage conditions, such as temperature control and light protection, which increases logistical complexity. Freeze-drying, or lyophilization, has been investigated to increase long-term stability; nevertheless, it necessitates appropriate cryoprotectants and may change the properties of nanoparticles.Thus, maintaining physicochemical stability over the course of the product's shelf life continues to be a significant formulation difficulty [56].
Despite the well-established nature of laboratory-scale preparation techniques such solvent evaporation and high-pressure homogenization, there are substantial obstacles when transferring these procedures to industrial-scale manufacture. It is technically challenging to achieve batch-to-batch uniformity in drug loading, encapsulation efficiency, and particle size.
Good Manufacturing Practice (GMP) requirements, which demand strict control over process parameters, sterile conditions for parenteral goods, and verified quality assurance procedures, must be followed in large-scale production. Concerns about residual solvent toxicity and environmental effects are raised by the use of organic solvents in several preparation techniques. Cost-effectiveness is still a crucial consideration, too. Production costs are higher than for traditional dosage forms because to the intricacy of nanoparticle composition, the requirement for specialist equipment, and quality control testing. Even though there are therapeutic benefits, these obstacles could prevent broad clinical use [57].
Nanomedicine regulatory channels are continually developing. Lipid nanoparticles, in contrast to traditional small-molecule medications, have intricate physicochemical properties that affect immunogenicity, pharmacokinetics, and biodistribution. Particle size, shape, surface charge, stability, and release kinetics must all be well characterized for regulatory bodies. Because changing biodistribution might alter safety and effectiveness profiles, proving bioequivalence with traditional formulations may not be enough for nanoformulations including well-known medications like methotrexate. Because of worries about immunogenicity and off-target consequences, regulatory monitoring is considerably more stringent in the case of biologic-loaded systems or gene-delivery platforms. The lack of widely accepted standards for evaluating nanomedicine makes approval procedures even more difficult. Prior to clinical licensure, developers must provide comprehensive preclinical toxicological data, pharmacokinetic investigations, and long-term safety evaluations [58].
Long-term safety evidence for lipid nanoparticles in RA treatment is still scarce, despite short-term preclinical research showing better therapeutic effects. Long-term therapy is necessary for chronic conditions like RA, which raises questions regarding cumulative toxicity and nanoparticle buildup in organs including the kidneys, liver, and spleen. Complement activation-related pseudoallergy (CARPA), oxidative stress brought on by lipid breakdown products, and immunological activation are possible hazards. Targeting ligands and surface alterations may also affect immunogenicity. Before adapting gene-delivery methods inspired by platforms like BNT162b2 to chronic inflammatory illnesses, long-term immunological effects must be carefully considered. Furthermore, variations in patient-specific variables such as immunological response, metabolic state, and illness severity may affect how nanoparticles behave in vivo. Therefore, extensive long-term clinical research is necessary to verify long-term safety and therapeutic efficacy [59].
FUTURE RESEARCH DIRECTIONS
Future studies on lipid-based nanotechnology for RA are anticipated to advance from traditional drug delivery to treatment platforms that are multifunctional, intelligent, and precision-driven. Because RA is so diverse in terms of immune cell activation patterns, cytokine expression profiles, hereditary predisposition, and treatment response variability, tailored nanomedicine is a viable avenue. Site-specific targeting and treatment response may be improved by customizing lipid nanocarriers based on patient biomarkers, such as varying expression of TNF-α, IL-6, or folate receptors on activated macrophages [60]. Nanoformulations including biologics or medications like methotrexate may be customized to maximize efficacy while reducing toxicity thanks to developments in pharmacogenomics and biomarker-guided treatment. This kind of strategy fits nicely with the larger trend in chronic inflammatory illnesses toward precision therapy [61]. It is also expected that machine learning and artificial intelligence (AI) would revolutionize nanocarrier optimization. Predicting drug–lipid interactions, release kinetics, encapsulation efficiency, nanoparticle behavior, and in vivo biodistribution can all be aided by AI-guided modeling. AI algorithms may find the ideal formulation parameters and speed up the creation of stable and scalable lipid systems by evaluating substantial datasets from preclinical and clinical research. Computational methods may also help with virtual screening of targeted ligands and lipid excipients, which will cut down on development time and experimental effort. The translational pipelines from lab research to clinical application might be greatly streamlined by combining AI with nanotechnology [62]. The creation of combination and multi-drug delivery systems is another crucial future path. Since RA pathogenesis includes several inflammatory pathways, complete disease management may not be possible with single-drug treatment. A flexible framework for co-encapsulating biologics, nucleic acids, or traditional DMARDs in a single carrier is offered by lipid nanoparticles. For example, combining methotrexate with antioxidants or anti-inflammatory siRNA in a single nanocarrier may provide synergistic therapeutic benefits while lowering dose requirements. Such multi-drug systems can be engineered to provide sequential or controlled release, thereby improving therapeutic precision and minimizing systemic exposure. This approach may improve long-term illness remission and lessen treatment resistance [63]. Another cutting-edge area is represented by intelligent and stimuli-responsive lipid systems. These sophisticated systems are made to react to pathogenic cues, including acidic pH, high reactive oxygen species (ROS), or particular enzymatic activity, that are seen in inflammatory joints. While reducing off-target effects, triggered medication release at the inflammatory site can improve therapeutic concentration locally. The potential of lipid nanoparticles that are redox-sensitive, pH-sensitive, or enzyme-responsive to provide on-demand medication release is being studied. Additionally, theranostic applications which allow for simultaneous diagnosis and therapy may be made possible by the incorporation of imaging agents into lipid carriers. Future RA treatments may integrate sophisticated gene-modulating techniques into intelligent lipid systems, motivated by the clinical efficacy of lipid nanoparticle platforms employed in nucleic acid delivery, such as BNT162b2 [64]. In general, it is anticipated that the combination of stimuli-responsive nanotechnology, multi-drug approaches, artificial intelligence, and customized medicine would revolutionize the treatment of RA. Translating these advancements into clinically feasible and patient-centered treatment options will need ongoing multidisciplinary cooperation amongst pharmacologists, nanotechnologists, rheumatologists, and regulatory scientists [65].
CONCLUSION
A possible method to get around the drawbacks of traditional rheumatoid arthritis (RA) treatment is the use of lipid-based nanocarrier systems. Platforms including solid lipid nanoparticles, nanostructured lipid carriers, and liposomes provide important therapeutic benefits by increasing solubility, improving pharmacokinetics, facilitating targeted synovial distribution, and lowering systemic toxicity. In preclinical models, nanoformulations of well-known medications like methotrexate and biologic medicines like adalimumab show increased effectiveness, underscoring the promise of nanotechnology to optimize both symptomatic and disease-modifying therapy strategies. Furthermore, lipid nanoparticles may make next-generation precision therapies in inflammatory illnesses possible, according to developments in nucleic acid therapy and gene delivery. Despite these promising advancements, stability, large-scale production, regulatory approval, and long-term safety issues must be resolved for clinical translation to be effective. Future studies combining stimuli-responsive platforms, multi-drug delivery systems, AI-guided formulation design, and tailored nanomedicine have great potential to redefine RA treatment. Lipid-based nanotherapeutics may close the gap between experimental innovation and patient-centered care by providing safer, more efficient, and more focused therapy approaches for chronic inflammatory illnesses with thorough clinical validation and interdisciplinary cooperation.
REFERENCES
Naman Agarwal*, Dr. Ajeet, Lipid Nanoparticle: Based Drug Delivery Systems in Rheumatoid Arthritis: Current Advances and Future Perspectives, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 5099-5119. https://doi.org/10.5281/zenodo.20302485
10.5281/zenodo.20302485